

Proj. Ref. No. BAC1-2022-08-0051-A

End-User Property and Supply Division, PGH

Project Supply and Delivery of Various Drugs and Medicines - Ampules/Vials

Opening of Bids: **16 September 2022**

ITEM NO.	QTY	UNIT	ITEM DESCRIPTION	ABC PER UNIT (PHP)	QUOTATIONS (all taxes included)	
					in figures	in words
			<b>AMPULES/VIALS</b>			
1	7,200	piece	Aciclovir 25mg/mL, 10mL vial (IV infusion)	198.82		
2	13,008	piece	Amikacin sulfate 125mg/mL, 2mL ampule/vial (IM, IV)	25.71		
3	16,080	piece	Amikacin sulfate 250mg/mL, 2mL ampule/vial (IM, IV)	224.47		
4	4,802	piece	Aminophylline (theophylline ethylenediamine) 25 mg/mL, 10 mL ampul (IV)	29.88		
5	16,340	piece	Ampicillin sodium 250mg vial (IM, IV)	34.53		
6	22,160	piece	Ampicillin sodium 500mg vial (IM, IV)	26.25		
7	1,081	piece	Amphotericin B Lipid Complex (as cholesteryl complex, colloidal dispersion) 50 mg vial (IV infusion)	11,332.44		
8	2,462	piece	Bupivacaine Hydrochloride 0.5%, 10mL ampul/vial (local infiltration)	80.26		
9	55,260	piece	Calcium Gluconate 10%, 10 mL ampul/vial (IV)	13.63		
10	1,520	piece	Carbetocin 100 mcg/mL, 1 mL ampule/vial, solution for Injection (IV)	979.65		
11	11,080	piece	Ciprofloxacin lactate 2mg/mL, 100mL vial (IV infusion)	17.25		
12	51,960	piece	Clindamycin phosphate 150mg/mL, 2mL ampule/vial (IM, IV)	68.25		
13	52,740	piece	Clindamycin phosphate 150mg/mL, 4mL ampule (IM, IV)	53.91		
14	4,102	piece	Cytarabine 100 mg/mL solution for injection, 5 mL	208.95		
15	4,102	piece	Cytarabine 100 mg/mL solution for injection, 10 mL	943.95		
16	4,000	piece	Diazepam 5 mg/mL, 2 mL ampul (IM, IV) (With PDEA Permit)	95.74		
17	6,002	piece	Doxorubicin Hydrochloride powder, 50mg vial or 2mg/mL, 25mL vial (IV)	628.95		
18	1,774	piece	Esmolol Hydrochloride 10mg/mL, 10mL vial (IV)	362.25		
19	12,555	piece	Gentamicin sulfate 40mg/mL, 2mL ampule/vial (IM, IV)	3.45		
20	23,380	piece	Glucose (dextrose) 50%, 50mL vial (IV)	14.07		
21	15,060	piece	Hydrocortisone sodium succinate 50mg/mL, 2mL vial or 100mg powder vial (IV)	17.25		
22	5,128	piece	Hydrocortisone sodium succinate 125 mg/mL, 2 mL vial (IV) or 250 mg powder vial (IV)	147.00		
23	5,951	piece	Levofloxacin 5 mg/mL solution for IV infusion, 100mL vial	66.61		
24	32,692	piece	Meropenem trihydrate 1g powder vial (IV)	151.67		
25	39,605	piece	Meropenem trihydrate 500mg powder vial (IV)	156.90		
26	5,040	piece	Mesna (sodium-2mercapto ethanesulphonate) 100mg/mL, 4mL ampule (IV)	147.00		
27	38,420	piece	Metoclopramide 5mg/mL, 2mL ampule (As Base and As Hydrochloride) (IM/IV)	16.00		
28	3,320	piece	Milrinone 10mg/ml, 10ml ampule (IV) (With Compassionate Special Permit)	890.40		
29	22,430	piece	Neostigmine 500 mcg/mL solution for injection (IM/IV/SC), 1 mL ampule	105.00		
30	4,600	piece	Octreotide acetate 100 micrograms/mL ampul (IV infusion)	515.22		
31	24,660	piece	Ondansetron 2mg/mL, 2mL ampule (IM, IV)	128.63		
32	33,800	piece	Oxacillin sodium 500mg vial (IM, IV)	13.53		
33	2,410	piece	Penicillin G crystalline (benzylpenicillin) sodium 1,000,000 units vial (IM, IV)	18.00		
34	1,630	piece	Penicillin G crystalline (benzylpenicillin) sodium 5,000,000 units vial (IM, IV)	30.00		
35	7,595	piece	Phytomenadione (phytonadione, vitamin K1) 10mg/mL, 1mL ampul (IM, IV, SC) (as mixed micelle)	52.38		
36	42,560	piece	Sodium bicarbonate 1mEq/mL, 20mL ampul/vial (adult) (IV infusion)	144.75		
37	1,658	piece	Suxamethonium (succinylcholine) chloride 20 mg/mL, 10 mL vial (IV)	133.82		
38	52,210	piece	Tramadol Hydrochloride 50mg/mL, 1mL ampule (IM, IV, SC)	8.65		
39	13,670	piece	Tramadol Hydrochloride 50mg/mL, 2mL ampule (IM, IV, SC)	59.00		
40	57,920	piece	Vancomycin Hydrochloride 500mg vial (IV)	129.96		
<b>TOTAL APPROVED BUDGET FOR THE CONTRACT: Ph78,744,287.16</b>						

Approved by:

Proj. Ref. No. BAC1-2022-08-0051-A

End-User Property and Supply Division, PGH

Project Supply and Delivery of Various Drugs and Medicines - Ampules/Vials

Opening of Bids: **16 September 2022**

Dean CHARLOTTE M. CHIONG, MD, PhD  
Chairperson

---

(Signature over Printed Name of President/Gen. Manager)

---

(Name & Address of Company)

## TERMS AND CONDITIONS

1. Indicate the **brand and packing of the item/s** offered.
2. The brand offered must be **at least five (5) years commercially available in the market from date of opening of bids**. Proof of this shall be the initial Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).
3. **Submit the following documents, submission should be per product, with tab and per item number. Two (2) copies for the Valid Certificate of Product Registration and Certificate of Analysis (COA).**
  - 3.1. **Memorandum of Agreement (MOA) and Certificate of exclusive/authorized distributorship between the manufacturer and distributor.**  
Distributors/suppliers must have certification from their principals that they are the exclusive distributor of the drug products authorized to tender for the product on behalf of the principal and that all commitments made by them shall be honored by the principal in case of termination of distributorship agreement.
  - 3.2. **Valid Certificate of Product Registration (CPR)** issued by the Food and Drug Administration (FDA).  
- The name of the respective distributor should appear on the submitted CPR of the drug.  
**Note: CPRs that will expire within three (3) months from the date of opening of bids should present the Official Receipt of renewal of application and Document Tracking log for the CPR from the FDA.**
  - 3.3. **Certificate of Analysis (COA)** for the products offered (batch to be delivered if awarded) duly issued by an FDA-accredited laboratory (local or foreign) and should contain information indicated in monograph of the drug. Sample analyzed must not be expired during the time of bidding. The result of assay submitted must be in the specific brand and should be in the exact dosage formulation of the drug being bidded. In cases where local laboratories are unavailable to perform drug assays, assays done abroad is accepted. The local COA is preferred and given more weight in the evaluation and awarding process.
  - 3.4. **A notarized certificate** that it is the innovator drug (if applicable).
  - 3.5. **Certificate of Good Manufacturing Process (CGMP).**
  - 3.6. **Valid License to Operate (LTO).**
  - 3.7. **A notarized certificate that the offered brand has not been subject to product complaint/product recall** for the past three (3) years.
  - 3.8. **Certificate of Acceptance** from at least three (3) major hospitals issued within the year and should be supported with Sales Invoice (for new item/brand offered only).
  - 3.9. **A notarized certificate** that there are sufficient stocks for the offered item/s for one (1) year.
4. The offered drug must conform to the latest Philippine Food and Drug Administration (FDA) Approved by:
  - 4.1. **For all tablets and capsules**
    - 4.1.1. **All tablets/capsules should be in foil or blister pack. A picture of the blister pack (front and back) should be submitted.**
    - 4.1.2. Each individual flap in the tablet or capsule blister pack should be labeled with the generic name. **Dean VICENTE Y. BELIZARIO, JR., M.D.**
    - 4.1.3. Dosage form and strength of the Active Pharmaceutical Ingredients (API) should appear on *Chairperson*
    - 4.1.4. Name of drug, lot or batch number and expiry date must appear on every standard blister pack/foil strip and on the container or inner packaging. However, if the product is not restricted for dispensing in quantities less than the standard blister pack or foil strip, the batch or lot number and expiry date should appear on each unit.
    - 4.1.5. Inner label must be the same as the outer label.

Proj. Ref. No. BAC1-2022-08-0051-A

End-User Property and Supply Division, PGH

Project Supply and Delivery of Various Drugs and Medicines - Ampules/Vials

Opening of Bids: **16 September 2022**

4.1.6. A complete drug literature/product insert must accompany the product.

5. The following must be complied with specific for **cytotoxic injectable drugs**.

5.1. For cytotoxic injectable drugs, winning bidders are required to provide *Material Safety Data Sheet (MSDS)* and to submit *Drug Profile* to the Pharmacy Department per company under the first Purchase Order.

5.2. Winning bidders for cytotoxic injectable drugs are required to provide at least three (3) spill kits per company under the first Purchase Order.

6. New brands offered shall be subject to further evaluation and shall require the following:

6.1. Validation of the submitted Certificate of Acceptance from at least three (3) major hospitals;

6.2. Justification from end-user/s to validate the acceptance of the good/s offered (to be facilitated by PGH-PSD).

7. For the supply and delivery of awarded drugs and medicines.

7.1. Delivery of the goods is required as stated in the request of the end-user, commencing on the 3rd working day of notification through confirmed fax/email that the approved Call-off/ Notice to Supplier (NTS) is already available for pick up.

7.2. Delivery schedule (whichever is applicable):

7.2.1. within seven (7) calendar days;

7.2.2. as may be called for;

7.2.3. staggered delivery within three (3) months

\* 50% of the total quantity within seven (7) calendar days and 25% each for the succeeding months

Note: The end-user has the right to adjust the quantity to be delivered depending on the actual need of the hospital

7.3. Deliveries shall have at least two (2) years expiration date.

7.4. Delivery of goods with product complaint shall be put on hold until receipt of the final decision of the PGH management whether to proceed with the acceptance or to cancel/return the items.

7.5. Delivered items found to be non-formulary at any given time shall be returned to the company and a credit memo shall be issued.

7.6. Stocks delivered are subject to random sampling for testing as to quality and conformity to label. Testing fee at supplier's expense.

7.7. Stocks with lot #/batch different from the submitted Certificate of Analysis (COA) will be subjected to testing as to quality and conformity to label. Testing fee at supplier's expense.

7.8. All items that had been pulled out for various reasons, a credit memo shall be issued by the Contractor within one (1) month, otherwise, a delinquent account shall be processed by UP Manila - PGH and the amount will be deducted from any amount due to Supplier.

7.9. It is understood that the Supplier is legally responsible to deliver all issued **CALL-OFF/s** (Purchase Order) and **failure to deliver the first** as scheduled shall mean automatic cancellation of the Call-Off and Notice to Execute Framework Agreement (NEFA). Purchase from other source for the same shall be effected immediately to provide the requirements of the hospital. Penalty to the defaulting contractor shall be charged accordingly.

8. Failure to comply with the submission of the required documents shall be ground for post-disqualification in accordance with RA 9184

9. Compliance with RA 9184 and other applicable laws.

Approved by:

Dean CHARLOTTE M. CHIONG, MD, PhD  
Chairperson

\_\_\_\_\_  
(Signature over Printed Name of President/Gen. Manager)

\_\_\_\_\_  
(Name & Address of Company)